Back to top

AbbVie (ABBV) Tops Q2 Earnings and Revenue

Read MoreHide Full Article

North Chicago, IL-based AbbVie Inc. (ABBV - Free Report) is best known for its autoimmune disease drug, Humira. AbbVie’s flagship product Humira is approved for several indications like rheumatoid arthritis (moderate to severe), moderately to severely active polyarticular juvenile idiopathic arthritis, active psoriatic arthritis, active ankylosing spondylitis, Crohn’s disease (moderate to severe), ulcerative colitis (moderate to severe), axial spondyloarthritis, pediatric Crohn’s disease, chronic plaque psoriasis (moderate to severe), and hidradenitis suppurativa (moderate to severe. Other key products include Imbruvica (cancer) and Viekira Pak (hepatitis C virus (HCV) treatment).

Humira, is a major contributor to AbbVie’s top line. While Humira will remain the key growth driver at AbbVie, the coming quarters will see investor focus remaining primarily on Viekira’s performance as well as pipeline updates.

Meanwhile, the Pharmacyclics acquisition has diversified AbbVie’s product portfolio with the addition of Imbruvica.

AbbVie’s performance has been mixed, with the pharmaceuticals company delivering positive surprises in the two of the past four quarter while recording in-line earnings in the other two. The average earnings beat over the last four quarters is 1.65%.

AbbVie Inc. Price and EPS Surprise

AbbVie Inc. Price and EPS Surprise | AbbVie Inc. Quote

Currently, AbbVie has a Zacks Rank #3 (Hold), but that could definitely change following the company’s earnings report which was just released. We have highlighted some of the key stats from this just-revealed announcement below:

Earnings: AbbVie's second-quarter earnings came in at $1.42 per share, beating the Zacks Consensus Estimate of $1.40.

Revenues: AbbVie posted revenues of $6.94 billion, marginally beating the Zacks Consensus Estimate of $6.93 billion.

Key Stats: Humira sales came in at $4.7 billion, up 14.9% year over year excluding currency impact. Second-quarter Imbruvica net revenues were $626 million, up 42.6% year over year.

2017 Outlook: AbbVie reiterated its previously issues outlook for 2017. The company maintains its adjusted EPS in the range of $5.44–$5.54. The Zacks Consensus Estimate is currently pegged at $5.52 per share.

Share Price Impact: Shares were up almost 2% in pre-market trading.

Check back later for our full write up on this AbbVie earnings report.

The Hottest Tech Mega-Trend of All                

Last year, it generated $8 billion in global revenues. By 2020, it's predicted to blast through the roof to $47 billion. Famed investor Mark Cuban says it will produce "the world's first trillionaries," but that should still leave plenty of money for regular investors who make the right trades early. See Zacks' 3 Best Stocks to Play This Trend >>

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

AbbVie Inc. (ABBV) - free report >>

More from Zacks Tale of the Tape

You May Like